skip to Main Content

Risdiplam is safe and effective in treating SMA type 2 and 3

  • 11 November 2019

The world may soon have a new, highly potent treatment for spinal muscular atrophy as Roche today announced that the key clinical trial of risdiplam has met its primary endpoint. Based on the trial data, which are also supported by TreatSMA’s own observations, risdiplam appears safe and highly effective in improving muscle function of children, adolescents and adults with SMA types 2 and 3 who have participated in the SUNFISH trial.

We are thrilled!

Read More

Physio with Marion – This Sunday

  • 26 October 2019

On the 27th October at 7pm TreatSMA is hosting a live webinar alongside physio Marion Main. This will be a regular slot at the end of each month. It can be viewed on all our social media platforms live and…

Read More
Back To Top